Reliance Global Group (EZRA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Mar, 2026Executive summary
The annual meeting will be held virtually on May 6, 2026, with a record date of March 5, 2026, for voting eligibility.
Five key proposals are up for shareholder vote, including director elections, auditor ratification, equity plan amendment, approval of share issuance under a purchase agreement, and adjournment authority.
The Board unanimously recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposal 1: Election of five directors for a one-year term expiring at the 2027 annual meeting.
Proposal 2: Ratification of Urish Popeck & Co., LLC as independent auditor for fiscal year 2026.
Proposal 3: Amendment to the 2025 Equity Incentive Plan to increase shares available for issuance by 14,000,000.
Proposal 4: Approval of share issuance under a $50 million equity line of credit with White Lion Capital, exceeding Nasdaq’s 20% cap.
Proposal 5: Authorization for the Board to adjourn the meeting if necessary to solicit more votes.
Board of directors and corporate governance
The Board consists of five members, all with significant experience in finance, insurance, and business management.
Three standing committees: Audit, Compensation, and Nominating & Governance, all composed of independent directors.
All directors attended at least 75% of meetings in 2025; all are expected to attend the 2026 annual meeting.
The Board partially combines the Chairman and CEO roles due to company size.
A Code of Ethics and Business Conduct applies to all employees, officers, and directors.
Latest events from Reliance Global Group
- Net loss improved to $1.4M as insurance growth and tech/life sciences investments advanced.EZRA
Q1 20268 May 2026 - All proposals passed, with leadership focused on growth and stockholder value.EZRA
AGM 20266 May 2026 - Strategic tech expansion, divestitures, and improved financials position for future growth.EZRA
Q4 20256 May 2026 - Strategic investment in Innervate Radiopharmaceuticals advances late-stage healthcare platform exposure.EZRA
Proxy filing4 May 2026 - Shareholders will vote on director elections, equity plan expansion, and a $50M share issuance.EZRA
Proxy Filing12 Mar 2026 - Q2 net loss improved 62%, Spetner deal to double revenue and boost profitability.EZRA
Q2 20242 Feb 2026 - Raising $5.3M for growth, tech, and digital assets amid dilution and Nasdaq compliance risks.EZRA
Registration Filing23 Jan 2026 - Q3 2024 delivered revenue growth, cost cuts, positive Adjusted EBITDA, and major M&A and tech moves.EZRA
Q3 202415 Jan 2026 - Revenue up 2%, net loss down 24%, and tech advances set stage for further growth.EZRA
Q4 202426 Dec 2025